Research map: Budget impact analysis of bivalent respiratory syncytial virus prefusion F (RSVpreF) maternal vaccination for preventing respiratory syncytial virus in Egyptian infants

Back to the article

Papers in this map

  1. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis · You Li · 2022 · 2024 citations · Cited by this paper
  2. The evolution of cellular therapies in sarcoma: Breakthroughs, challenges, and future directions · Chalothorn Wannaphut · 2026 · Related
  3. Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants · Beate Kampmann · 2023 · 1005 citations · Cited by this paper
  4. Pneumococcal vaccination awareness and uptake among high-risk patients attending internal medicine outpatient clinics: A cross-sectional study · 2026 · Related
  5. Latitudinal Variations in Seasonal Activity of Influenza and Respiratory Syncytial Virus (RSV): A Global Comparative Review · Kimberly Bloom‐Feshbach · 2013 · 455 citations · Cited by this paper
  6. Route of BCG administration determines success · 2026 · Related
  7. Respiratory Syncytial Virus–Associated Hospitalizations Among Young Children: 2015–2016 · Brian Rha · 2020 · 280 citations · Cited by this paper
  8. Safety monitoring of bivalent, quadrivalent, and 9-valent human papillomavirus vaccination in Japan: The vaccine effectiveness, networking, and universal safety (VENUS) study · 2026 · Related
  9. Respiratory Syncytial Virus Transplacental Antibody Transfer and Kinetics in Mother-Infant Pairs in Bangladesh · Helen Y. Chu · 2014 · 193 citations · Cited by this paper
  10. Immunological insights into why pertussis continues to be endemic · 2026 · Related
  11. Waning of Maternal Antibodies Against Measles, Mumps, Rubella, and Varicella in Communities With Contrasting Vaccination Coverage · Sandra Waaijenborg · 2013 · 187 citations · Cited by this paper
  12. Vaccination coverage and influencing factors of four non‑National Immunization Program vaccines: A cross‑sectional survey among children aged 1‒6 years in Beijing, China · 2026 · Related
  13. Durability of Anti-Spike Antibodies in Infants After Maternal COVID-19 Vaccination or Natural Infection · Lydia L. Shook · 2022 · 182 citations · Cited by this paper
  14. Estimating clinical and economic impacts and cost-effectiveness of introducing 20-valent pneumococcal conjugate vaccine in Taiwan’s pediatric National Immunization Program and impacts of a delayed implementation · 2026 · Related
  15. Efficacy, Safety, and Immunogenicity of the MATISSE (Maternal Immunization Study for Safety and Efficacy) Maternal Respiratory Syncytial Virus Prefusion F Protein Vaccine Trial · Eric A. F. Simões · 2025 · 112 citations · Cited by this paper
  16. Health-related quality of life and adverse events during 14 days after receiving a live-attenuated influenza vaccine in Japanese children 4–15 years of age · 2026 · Related
  17. Defining the Risk and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Preterm Infants Without Chronic Lung Disease or Congenital Heart Disease · J. Figueras Aloy · 2016 · 107 citations · Cited by this paper
  18. Spatial accessibility analysis of vaccination units in Gansu Province, China (2025) · 2026 · Related
  19. Real-world effectiveness of RSVpreF vaccination during pregnancy against RSV-associated lower respiratory tract disease leading to hospitalisation in infants during the 2024 RSV season in Argentina (BERNI study): a multicentre, retrospective, test-negative, case–control study · Gonzalo Pérez Marc · 2025 · 95 citations · Cited by this paper
  20. Randomized controlled trial evaluating immunogenicity and safety of a porcine circovirus-free rotavirus vaccine in healthy Chinese infants · 2026 · Related
  21. Estimating the impact of multiple immunization products on medically-attended respiratory syncytial virus (RSV) infections in infants · Gabriel Rainisch · 2019 · 71 citations · Cited by this paper
  22. Bivalent prefusion F vaccination in pregnancy and respiratory syncytial virus hospitalisation in infants in the UK: results of a multicentre, test-negative, case-control study · Thomas Christie Williams · 2025 · 43 citations · Cited by this paper
  23. Incidence and Clinical Features of Respiratory Syncytial Virus Infections in a Population-Based Surveillance Site in the Nile Delta Region · Emily Rowlinson · 2013 · 40 citations · Cited by this paper
  24. Acute lower respiratory tract infection due to respiratory syncytial virus in a group of Egyptian children under 5 years of age · Aya Mohamed Fattouh · 2011 · 31 citations · Cited by this paper
  25. Preterm, early term, and post-term infants from Riyadh mother and baby multicenter cohort study: The cohort profile · Amel Ahmed Fayed · 2022 · 22 citations · Cited by this paper
  26. The burden of Respiratory Syncytial Virus (RSV) infection in the Middle East and North Africa (MENA) region across age groups: A systematic review · Yolla Youssef · 2021 · 20 citations · Cited by this paper
  27. Cost-effectiveness Analysis of Maternal Immunization with RSVpreF Vaccine for the Prevention of Respiratory Syncytial Virus Among Infants in Spain · Javier Álvarez Aldeán · 2024 · 18 citations · Cited by this paper
  28. Multicenter study to describe viral etiologies, clinical profiles, and outcomes of hospitalized children with severe acute respiratory infections, Egypt 2022 · Amr Kandeel · 2023 · 17 citations · Cited by this paper
  29. Cost-effectiveness of bivalent respiratory syncytial virus Prefusion F (RSVpreF) maternal vaccine among infants in the United States · Ahuva Averin · 2025 · 10 citations · Cited by this paper
  30. Economic and Clinical Benefits of Bivalent Respiratory Syncytial Virus Prefusion F (RSVpreF) Maternal Vaccine for Prevention of RSV in Infants: A Cost-Effectiveness Analysis for Mexico · Jose Luis Huerta · 2025 · 3 citations · Cited by this paper
  31. Budget impact of maternal vaccination with RSVpreF to protect privately insured infants in Dubai against respiratory syncytial virus · Mostafa Zayed · 2025 · 3 citations · Cited by this paper

Source: OpenAlex (CC0)